SSR128129E is a small molecule inhibitor of fibroblast growth factor receptor (FGFR) that has been investigated as a potential treatment for cancer. FGFR is a protein that plays a key role in cell growth and development, and its dysregulation has been linked to various types of cancer. In this article, we will discuss SSR128129E's chemical properties, health benefits, potential effects, product mechanism, safety, side effects, dosing information, and conclusion.
Chemical name:
The chemical name of SSR128129E is N-[(3S)-1-[2-(2-methoxyphenylamino)pyrimidin-4-yl]-3-piperidinyl]-N'-(3-methylphenyl)urea.
Molecular formula:
The molecular formula of SSR128129E is C24H29N5O2.
Formula weight:
The formula weight of SSR128129E is 419.52 g/mol.
CAS No:
The CAS No of SSR128129E is 848318-25-2.
Top ten keywords from Google and Synonyms Synonym:
Synonyms:
Health benefits of this product:
SSR128129E is being developed as a potential treatment for solid tumors that are driven by the dysregulation of FGFR signaling. Preclinical studies have shown that the drug has potent anti-tumor activity against various types of cancer, including breast, lung, and bladder cancers, among others. It may also have the potential to overcome resistance to other cancer treatments such as chemotherapy and targeted therapies.
Potential effects:
Since SSR128129E is still in the early stages of clinical development, its potential effects are not yet fully understood. However, preclinical studies have demonstrated that it has potent anti-tumor activity against a range of solid tumors driven by FGFR dysregulation. The drug may also have the potential to overcome resistance to other cancer treatments, such as chemotherapy and targeted therapies.
Product mechanism:
FGFRs play a key role in cell growth and development by regulating cell proliferation, survival, and differentiation. Dysregulation of FGFR signaling has been implicated in tumor growth and progression. SSR128129E works by inhibiting the activity of FGFRs, thereby blocking the downstream signaling pathways that promote tumor growth and survival. This mechanism of action makes it a promising therapeutic option for the treatment of FGFR-driven cancers.
Safety:
As with all investigational drugs, the safety of SSR128129E is still being evaluated in clinical trials. In preclinical studies, the drug was well-tolerated with no significant toxicities observed at therapeutic doses. However, adverse events such as nausea, vomiting, and fatigue have been reported in early clinical trials. Patients receiving SSR128129E should be closely monitored for any signs of adverse reactions.
Side effects:
Common side effects of SSR128129E may include nausea, vomiting, fatigue, and diarrhea. More serious side effects such as liver toxicity and cardiac events have been reported in some patients in early clinical trials. Patients receiving SSR128129E should be closely monitored for any signs of adverse reactions and should report any symptoms to their healthcare provider.
Dosing information:
SSR128129E is administered orally, and the recommended dose varies depending on the specific type of cancer being treated. Clinical trials are currently underway to determine the optimal dosing regimen for SSR128129E. Patients receiving SSR128129E should follow their healthcare provider's instructions regarding dosing and administration.
Conclusion:
SSR128129E is a promising new drug being developed as a potential treatment for solid tumors that are driven by the dysregulation of FGFR signaling. It works by inhibiting the activity of FGFRs, thereby blocking the downstream signaling pathways that promote tumor growth and survival. While the drug is still in the early stages of clinical development, preclinical studies suggest that it has potent anti-tumor activity and may be able to overcome resistance to other cancer treatments. However, more research is needed to fully understand its potential benefits, risks, and optimal dosing regimen
